Table 2.

Meta-analysis of the APOA5 -1131T>C polymorphism and blood lipids association (excluding the outlier studies)

Group and subgroups under analysis	Comparisons (n)	Q test P value	SMD (95% CI)	P
LDL-C
All	34	0.28	0.03 (-0.01, 0.06)	0.12
All in HWE	31	0.28	0.02 (-0.02, 0.06)	0.34
No lipid-lowering medicine	15	0.76	-0.00 (-0.06, 0.06)	0.94
No lipid-lowering medicine in HWE	14	0.69	-0.00 (-0.06, 0.06)	0.96
European	10	0.26	0.05 (-0.04, 0.13)	0.27
European in HWE	8	0.14	0.05 (-0.06, 0.16)	0.38
East Asian	18	0.24	0.02 (-0.03, 0.07)	0.37
East Asian in HWE	17	0.40	0.00 (-0.05, 0.06)	0.87
Healthy	7	0.18	-0.00 (-0.11, 0.11)	0.98
Type 2 diabetes	7	0.36	-0.01 (-0.11, 0.10)	0.89
Male	4	0.14	0.01 (-0.17, 0.19)	0.94
Male in HWE	3	0.07	-0.01 (-0.30, 0.29)	0.96
HDL-C
All	44	0.55	-0.15 (-0.18, -0.13)	<0.00001
All in HWE	41	0.66	-0.15 (-0.17, -0.12)	<0.00001
No lipid-lowering medicine	21	0.66	-0.15 (-0.20, -0.10	<0.00001
No lipid-lowering medicine in HWE	20	0.61	-0.15 (-0.20, -0.10)	<0.00001
European	12	0.46	-0.11 (-0.17, -0.05)	0.0005
European in HWE	10	0.29	-0.12 (-0.20, -0.04)	0.005
East Asian	23	0.71	-0.18 (-0.21, -0.15)	<0.00001
East Asian in HWE	22	0.80	-0.17 (-0.20, -0.13)	<0.00001
Other	9	0.74	-0.10 (-0.16, -0.03)	0.004
CHD	4	0.61	-0.12 (-0.23, -0.01)	0.04
CHD in HWE	3	0.42	-0.12 (-0.24, -0.01)	0.04